Literature DB >> 23276484

The new risk adjustment formula in Germany: implementation and first experiences.

Florian Buchner1, Dirk Goepffarth, Juergen Wasem.   

Abstract

In Germany risk adjustment is a core element of the regulatory framework of competition between sickness funds. It shall create a level playing field between funds with very heterogeneous risk structures. Prior to 2009 risk adjustment was mainly by a demographic model. In 2009 morbidity based risk adjustment was introduced, embedded in a broader reform of the statutory health insurance system. The new formula covers 80 "severe" or "costly and chronic" diseases structured in a system of hierarchical groups. The performance of the new system was evaluated by the Advisory Board of Scientific Experts on Risk Adjustment to the Federal Insurance Office. The evaluation is based on the data of the first year 2009. Individual level as well as group level performance improved considerably comparing to the old model. Also predictive accuracy on the sickness funds level improved. The evaluation analyzed coding and prescription patterns in a joint point analyses. No changes of coding behavior which can be ascribed to the introduction of the new system were found. Some issues for further improvement were identified: A systematic underpayment for higher age groups is observed due to not annualizing the costs of the deceased. Systematic underpayment for multi-morbidity and systematic over-payment for those without any medical conditions can also be observed, although the level of over-/underpayment was clearly reduced compared to the old model.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Mesh:

Year:  2012        PMID: 23276484     DOI: 10.1016/j.healthpol.2012.12.001

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  12 in total

1.  Overpaying morbidity adjusters in risk equalization models.

Authors:  R C van Kleef; R C J A van Vliet; W P M M van de Ven
Journal:  Eur J Health Econ       Date:  2015-09-29

2.  On the calculation of the Israeli risk adjustment rates.

Authors:  Amir Shmueli
Journal:  Eur J Health Econ       Date:  2014-02-28

3.  Sources of European drug consumption data at a country level.

Authors:  Pili Ferrer; Elena Ballarín; Mònica Sabaté; Joan-Ramon Laporte; Marieke Schoonen; Marietta Rottenkolber; Joan Fortuny; Joerg Hasford; Iain Tatt; Luisa Ibáñez
Journal:  Int J Public Health       Date:  2014-05-30       Impact factor: 3.380

4.  Measuring customer preferences in the German statutory health insurance.

Authors:  Jonas B Pendzialek; Dusan Simic; Stephanie Stock
Journal:  Eur J Health Econ       Date:  2016-09-21

5.  Development and validation of risk-adjustment models for elective, single-level posterior lumbar spinal fusions.

Authors:  David N Bernstein; Aakash Keswani; Debbie Chi; James E Dowdell; Samuel C Overley; Saad B Chaudhary; Addisu Mesfin
Journal:  J Spine Surg       Date:  2019-03

6.  Pharmaceutical cost management in an ambulatory setting using a risk adjustment tool.

Authors:  David Vivas-Consuelo; Ruth Usó-Talamantes; Natividad Guadalajara-Olmeda; José-Luis Trillo-Mata; Carla Sancho-Mestre; Laia Buigues-Pastor
Journal:  BMC Health Serv Res       Date:  2014-10-21       Impact factor: 2.655

7.  A voluntary deductible in health insurance: the more years you opt for it, the lower your premium?

Authors:  K P M van Winssen; R C van Kleef; W P M M van de Ven
Journal:  Eur J Health Econ       Date:  2016-02-09

8.  Improving risk equalization using information on physiotherapy diagnoses.

Authors:  Frank Eijkenaar; René C J A van Vliet
Journal:  Eur J Health Econ       Date:  2017-02-09

9.  Risk equalization in competitive health insurance markets: Identifying healthy individuals on the basis of multiple-year low spending.

Authors:  Frank Eijkenaar; René C J A van Vliet; Richard C van Kleef
Journal:  Health Serv Res       Date:  2018-10-16       Impact factor: 3.402

10.  Using Diagnoses to Estimate Health Care Cost Risk in Canada.

Authors:  Yin Li; Sharada Weir; Mitch Steffler; Shaun Shaikh; James G Wright; Jasmin Kantarevic
Journal:  Med Care       Date:  2019-11       Impact factor: 2.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.